Table V.
LTβR, p-p65 and p52 protein expression in the different BCa groups classified by clinical indicator.
| LTβR | p-p65 | p52 | ||||
|---|---|---|---|---|---|---|
|
|
|
|
||||
| Clinical indicator (N) | Positive rate (%) | MD ×10 (mean ± SD) | Positive rate (%) | MD ×10 (mean ± SD) | Positive rate (%) | MD ×10 (mean ± SD) |
| Age | ||||||
| ≥65 (41) | 78.0 | 6.1±2.3 | 53.7 | 3.4±1.6 | 61.0 | 3.8±2.0 |
| <65 (32) | 59.4 | 5.6±2.3a | 59.4 | 3.6±1.6a | 65.6 | 4.3±1.9a |
| Gender | ||||||
| Male (54) | 70.4 | 6.0±2.3 | 57.4 | 3.6±1.6 | 63.0 | 4.1±2.0 |
| Female (19) | 68.4 | 5.6±2.2a | 52.6 | 3.0±1.8a | 63.2 | 3.9±1.9a |
| Histological grade | ||||||
| PUNLMP + G1 (32) | 56.3 | 4.6±1.7 | 40.6 | 2.6±1.3 | 50.0 | 3.2±1.7 |
| G2 (20) | 75.0 | 6.5±2.0 | 60.0 | 3.6±1.3 | 60.0 | 4.3±1.8 |
| G3 (21) | 85.7 | 7.3±2.3b | 76.2 | 4.7±1.6b | 85.7 | 5.1±2.1b |
| Clinical stage | ||||||
| Ta + T1 (37) | 54.1 | 4.8±1.9 | 40.5 | 2.8±1.4 | 43.2 | 3.4±1.7 |
| ≥T2 (36) | 86.1 | 6.9±2.2b | 72.2 | 4.1±1.6b | 83.3 | 4.7±2.0b |
| Lymph node metastasis | ||||||
| Negative (48) | 58.3 | 5.2±2.1 | 52.1 | 3.1±1.4 | 54.2 | 3.6±1.9 |
| Positive (25) | 92.0 | 7.2±2.3b | 64.0 | 4.2±1.8b | 80.0 | 4.8±1.9b |
a
P>0.05;
b
P<0.05.
LTβR, lymphotoxin β receptor; p-p65, phosphorylated p65; BCa, bladder cancer; MD, mean density; SD, standard deviation; PUNLMP, papillary urothelial neoplasm of low malignant potential.